And then there was one: GRN1005 failure leaves Geron with imetelstat and $90m

The good news for Geron's investors? Now that the Menlo Park, California-based company has terminated development of GRN1005 and plans to lay off 64 of its 107 employees, it has enough cash on hand to fund its operations for two or three years.

More from Anticancer

More from Therapeutic Category